p21Waf/CIP1 is a small unstructured protein that binds and inactivates cyclin-dependent
kinases (CDKs). To this end, p21 levels increase following the activation of the p53 tumor …

DNA damage tolerance and mutagenesis are hallmarks and enabling characteristics of
neoplastic cells that drive tumorigenesis and allow cancer cells to resist therapy. The 'Y …

Intrinsic and acquired drug resistance and induction of secondary malignancies limit
successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to …

DNA polymerase ζ (Polζ) belongs to the same B-family as high-fidelity replicative
polymerases, yet is specialized for the extension reaction in translesion DNA synthesis …

Fanconi anemia (FA) is a recessive genetic disorder caused by biallelic mutations in at least
one of 22 FA genes. Beyond its pathological presentation of bone marrow failure and …

DNA damaging chemotherapy is the first line of treatment for certain cancers, but its
longterm success is often marred by the eventual acquisition of chemoresistance. Other …

Approximately half of high-grade serous epithelial ovarian cancers incur alterations in genes
of homologous recombination (BRCA1, BRCA2, RAD51C, Fanconi anemia genes), and the …

The HORMA domain protein REV7, also known as MAD2L2, interacts with a variety of
proteins and thereby contributes to the establishment of different complexes. With doing so …

DNA replication stress describes a state of impaired replication fork progress that triggers a
cellular stress response to maintain genome stability and complete DNA synthesis …

Abstract Aurora Kinase B (AURKB) and Mitotic Arrest Deficient 2 Like 2 (MAD2L2) are
emerging anticancer therapeutic targets. AURKB and MAD2L2 are the least well studied …